Literature DB >> 20795760

Shipping of therapeutic somatic cell products.

Theresa L Whiteside1, Deborah L Griffin, Joanna Stanson, William Gooding, David McKenna, Darin Sumstad, Diane Kadidlo, Adrian Gee, April Durett, Robert Lindblad, Deborah Wood, David Styers.   

Abstract

BACKGROUND AIMS: Shipment of therapeutic somatic cells between a current good manufacturing practice (cGMP) facility and a clinic or between different cGMP facilities requires validated standard operating procedures (SOP). Under National Heart Lung & Blood Institute (NHLBI) sponsorship, the Production Assistance for Cellular Therapies (PACT) group conducted a validation study for the shipping SOP it has created, including shipments of cryopreserved somatic cells, fresh peripheral blood specimens and apheresis products.
METHODS: Comparisons of pre- and post-shipped cells and cell products at the three participating facilities included measurements of viability, phenotypic profiles and cellular functions. The data were analyzed at the University of Pittsburgh Biostatistics Facility.
RESULTS: No consistent shipping effects on cell viability, phenotype or functions were detected for cryopreserved and shipped peripheral blood mononuclear cells (PBMC), monocytes, immature dendritic cells (iDC), NK-92 or cytotoxic T cells (CTL). Cryopreserved mesenchymal stromal cells (MSC) had a significantly decreased viability after shipment, but this effect was in part because of inter-laboratory variability in the viable cell counts. Shipments of fresh peripheral blood and apheresis products for the generation of CTL and dendritic cells (DC), respectively, had no significant effects on cell product quality. MSC were successfully generated from fresh bone marrow samples shipped overnight.
CONCLUSIONS: This validation study provides a useful set of data for guiding shipments of therapeutic somatic cells in multi-institutional clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20795760      PMCID: PMC7982143          DOI: 10.3109/14653249.2010.506507

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  14 in total

1.  Liquid storage, shipment, and cryopreservation of cord blood.

Authors:  Allison Hubel; Dale Carlquist; Mary Clay; Jeff McCullough
Journal:  Transfusion       Date:  2004-04       Impact factor: 3.157

2.  Retention of cellular properties of PBPCs following liquid storage and cryopreservation.

Authors:  Gary Moroff; Shalini Seetharaman; James W Kurtz; Nicholas J Greco; Michael D Mullen; Thomas A Lane; Ping Law
Journal:  Transfusion       Date:  2004-02       Impact factor: 3.157

Review 3.  Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay.

Authors:  T L Whiteside; J Bryant; R Day; R B Herberman
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

4.  Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).

Authors:  Barbara Savoldo; John A Goss; Markus M Hammer; Lan Zhang; Teresita Lopez; Adrian P Gee; Yu-Feng Lin; Ruben E Quiros-Tejeira; Petra Reinke; Stephan Schubert; Stephen Gottschalk; Milton J Finegold; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop
Journal:  Blood       Date:  2006-07-11       Impact factor: 22.113

5.  Development of a potency assay for human dendritic cells: IL-12p70 production.

Authors:  Lisa H Butterfield; William Gooding; Theresa L Whiteside
Journal:  J Immunother       Date:  2008-01       Impact factor: 4.456

Review 6.  Cell therapies: realizing the potential of this new dimension to medical therapeutics.

Authors:  Pawanbir Singh; David J Williams
Journal:  J Tissue Eng Regen Med       Date:  2008-08       Impact factor: 3.963

Review 7.  Engineering lymphocyte subsets: tools, trials and tribulations.

Authors:  Carl H June; Bruce R Blazar; James L Riley
Journal:  Nat Rev Immunol       Date:  2009-10       Impact factor: 53.106

8.  Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.

Authors:  S Arai; R Meagher; M Swearingen; H Myint; E Rich; J Martinson; H Klingemann
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

Review 9.  Therapeutic implications of Cancer Initiating Cells.

Authors:  Alessandro Scopelliti; Patrizia Cammareri; Veronica Catalano; Vitanna Saladino; Matilde Todaro; Giorgio Stassi
Journal:  Expert Opin Biol Ther       Date:  2009-08       Impact factor: 4.388

Review 10.  Mesenchymal stem cells and their use as cell replacement therapy and disease modelling tool.

Authors:  J García-Castro; C Trigueros; J Madrenas; J A Pérez-Simón; R Rodriguez; P Menendez
Journal:  J Cell Mol Med       Date:  2008-12       Impact factor: 5.310

View more
  9 in total

1.  The sensitivity of human mesenchymal stem cells to vibration and cold storage conditions representative of cold transportation.

Authors:  N I Nikolaev; Y Liu; H Hussein; D J Williams
Journal:  J R Soc Interface       Date:  2012-05-23       Impact factor: 4.118

2.  Successful "in-flight" activation of natural killer cells during long-distance shipping.

Authors:  Scott A Koepsell; Diane M Kadidlo; Susan Fautsch; Jeffrey McCullough; Hans Klingemann; John E Wagner; Jeffrey S Miller; David H McKenna
Journal:  Transfusion       Date:  2012-05-11       Impact factor: 3.157

3.  An update from the United States National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: a decade of cell therapy.

Authors:  Deborah Wood; Robin Wesselschmidt; Peiman Hematti; Adrian P Gee; Cliona Rooney; Leslie Silberstein; Myriam Armant; Larry Couture; John E Wagner; David H McKenna; Derek Hei; Traci Heath Mondoro; Lisbeth Welniak; Robert Lindblad
Journal:  Clin Transl Sci       Date:  2014-03-21       Impact factor: 4.689

4.  Viable mononuclear cell stability study for implementation in a proficiency testing program: impact of shipment conditions.

Authors:  Olga A Kofanova; Kristine Davis; Barbara Glazer; Yvonne De Souza; Joseph Kessler; Fotini Betsou
Journal:  Biopreserv Biobank       Date:  2014-06       Impact factor: 2.300

5.  Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke.

Authors:  Quynh Vu; Kate Xie; Mark Eckert; Weian Zhao; Steven C Cramer
Journal:  Neurology       Date:  2014-03-07       Impact factor: 9.910

6.  Establishing a stem cell culture laboratory for clinical trials.

Authors:  Elíseo Joji Sekiya; Andresa Forte; Telma Ingrid Borges de Bellis Kühn; Felipe Janz; Sérgio Paulo Bydlowski; Adelson Alves
Journal:  Rev Bras Hematol Hemoter       Date:  2012

7.  Shipping blood to a central laboratory in multicenter clinical trials: effect of ambient temperature on specimen temperature, and effects of temperature on mononuclear cell yield, viability and immunologic function.

Authors:  Walter C Olson; Mark E Smolkin; Erin M Farris; Robyn J Fink; Andrea R Czarkowski; Jonathan H Fink; Kimberly A Chianese-Bullock; Craig L Slingluff
Journal:  J Transl Med       Date:  2011-03-08       Impact factor: 5.531

Review 8.  It's time to bring dendritic cell therapy to type 1 diabetes.

Authors:  Rémi J Creusot; Nick Giannoukakis; Massimo Trucco; Michael J Clare-Salzler; C Garrison Fathman
Journal:  Diabetes       Date:  2014-01       Impact factor: 9.461

Review 9.  The National Heart, Lung, and Blood Institute-funded Production Assistance for Cellular Therapies (PACT) program: Eighteen years of cell therapy.

Authors:  Ashraf El Fiky; Laarni Ibenana; Robert Anderson; Joshua M Hare; Aisha Khan; Adrian P Gee; Cliona Rooney; David H McKenna; Joseph Gold; Linda Kelley; Martha S Lundberg; Lisbeth A Welniak; Robert Lindblad
Journal:  Clin Transl Sci       Date:  2021-07-19       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.